SG11202104217QA - Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof - Google Patents
- ️Fri May 28 2021
SG11202104217QA - Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof - Google Patents
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereofInfo
-
Publication number
- SG11202104217QA SG11202104217QA SG11202104217QA SG11202104217QA SG11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA SG 11202104217Q A SG11202104217Q A SG 11202104217QA Authority
- SG
- Singapore Prior art keywords
- antibodies
- family
- sequence similarity
- similarity
- sequence Prior art date
- 2019-01-02
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962787711P | 2019-01-02 | 2019-01-02 | |
US201962838190P | 2019-04-24 | 2019-04-24 | |
PCT/IB2019/061461 WO2020141452A1 (en) | 2019-01-02 | 2019-12-31 | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104217QA true SG11202104217QA (en) | 2021-05-28 |
ID=71407016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104217QA SG11202104217QA (en) | 2019-01-02 | 2019-12-31 | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220144932A1 (en) |
EP (1) | EP3906260A4 (en) |
JP (2) | JP2022515960A (en) |
KR (2) | KR20240049652A (en) |
CN (2) | CN113195533B (en) |
AU (1) | AU2019418141A1 (en) |
BR (1) | BR112021008114A2 (en) |
CA (1) | CA3117619A1 (en) |
MX (1) | MX2021004504A (en) |
SG (1) | SG11202104217QA (en) |
WO (1) | WO2020141452A1 (en) |
Families Citing this family (3)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2838814T3 (en) * | 2012-02-15 | 2021-07-02 | Neuracle Science Co Ltd | FAM19A5 for use in the diagnosis and treatment of CNS damage |
CA3115797A1 (en) * | 2018-10-16 | 2020-04-23 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies |
EP4367128A1 (en) * | 2021-07-08 | 2024-05-15 | Neuracle Science Co., Ltd. | Polypeptide inhibitors and uses thereof |
Family Cites Families (9)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2838814T3 (en) | 2012-02-15 | 2021-07-02 | Neuracle Science Co Ltd | FAM19A5 for use in the diagnosis and treatment of CNS damage |
KR101802411B1 (en) * | 2015-02-17 | 2017-11-29 | 울산대학교 산학협력단 | Composition for preventing or treating of obesity comprising FAM19A5 and screening method for agent for treatment of obesity using the same |
KR102431830B1 (en) | 2016-11-07 | 2022-08-16 | 주식회사 뉴라클사이언스 | Anti-family 19, member A5 antibodies with sequence similarity and methods of use thereof |
US11746149B2 (en) * | 2017-06-27 | 2023-09-05 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma |
CA3067923A1 (en) * | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Anti-fam19a5 antibodies and uses thereof |
KR102454460B1 (en) * | 2017-06-27 | 2022-10-17 | 주식회사 뉴라클사이언스 | Use of anti-FAM19A5 antibody for the treatment of cancer |
KR102340352B1 (en) * | 2017-06-27 | 2021-12-21 | 주식회사 뉴라클사이언스 | Use of an anti-FAM19A5 antibody for the treatment of fibrosis |
WO2019207513A1 (en) * | 2018-04-24 | 2019-10-31 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain |
CN119662732A (en) * | 2018-05-08 | 2025-03-21 | 纽洛可科学有限公司 | Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies |
-
2019
- 2019-12-31 MX MX2021004504A patent/MX2021004504A/en unknown
- 2019-12-31 SG SG11202104217QA patent/SG11202104217QA/en unknown
- 2019-12-31 KR KR1020247011553A patent/KR20240049652A/en active Pending
- 2019-12-31 US US17/290,154 patent/US20220144932A1/en active Pending
- 2019-12-31 CN CN201980072221.0A patent/CN113195533B/en active Active
- 2019-12-31 JP JP2021523498A patent/JP2022515960A/en active Pending
- 2019-12-31 AU AU2019418141A patent/AU2019418141A1/en active Pending
- 2019-12-31 CA CA3117619A patent/CA3117619A1/en active Pending
- 2019-12-31 BR BR112021008114-3A patent/BR112021008114A2/en unknown
- 2019-12-31 WO PCT/IB2019/061461 patent/WO2020141452A1/en unknown
- 2019-12-31 CN CN202410112677.8A patent/CN117964756A/en active Pending
- 2019-12-31 EP EP19906712.5A patent/EP3906260A4/en active Pending
- 2019-12-31 KR KR1020217016663A patent/KR102656738B1/en active Active
-
2023
- 2023-01-26 JP JP2023010422A patent/JP2023052664A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3117619A1 (en) | 2020-07-09 |
US20220144932A1 (en) | 2022-05-12 |
CN113195533B (en) | 2024-04-26 |
JP2022515960A (en) | 2022-02-24 |
EP3906260A1 (en) | 2021-11-10 |
CN113195533A (en) | 2021-07-30 |
KR20240049652A (en) | 2024-04-16 |
MX2021004504A (en) | 2021-10-01 |
EP3906260A4 (en) | 2022-08-31 |
AU2019418141A1 (en) | 2021-05-27 |
WO2020141452A1 (en) | 2020-07-09 |
KR102656738B1 (en) | 2024-04-16 |
CN117964756A (en) | 2024-05-03 |
KR20210068608A (en) | 2021-06-09 |
JP2023052664A (en) | 2023-04-11 |
BR112021008114A2 (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3790898A4 (en) | 2022-03-02 | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
IL276830A (en) | 2020-10-29 | Anti-claudin 18.2 antibodies and uses thereof |
SG11202007074PA (en) | 2020-08-28 | Anti-claudin 18.2 antibodies and uses thereof |
SG11202110145SA (en) | 2021-10-28 | Antibodies against sars-cov-2 and methods of using the same |
IL276731A (en) | 2020-09-30 | Anti-cd73 antibodies and methods of use thereof |
EP3878863A4 (en) | 2022-06-22 | Anti-claudin18.2 antibody and use thereof |
IL278821A (en) | 2021-01-31 | Anti-sirpa antibodies and methods of use thereof |
SG11202108398YA (en) | 2021-08-30 | Anti-claudin 18 antibodies and methods of use thereof |
SG11202010909RA (en) | 2020-12-30 | Anti-msr1 antibodies and methods of use thereof |
ZA202106880B (en) | 2023-02-22 | Anti-claudin 18.2 antibody and application thereof |
ZA202103061B (en) | 2022-10-26 | Anti-cldn18.2 antibody and uses thereof |
EP4335874A3 (en) | 2024-05-29 | Anti-hla-g antibodies and use thereof |
EP3645044A4 (en) | 2021-04-28 | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of glaucoma |
IL270214A (en) | 2020-01-30 | Anti-sortilin antibodies and methods of use thereof |
IL279648A (en) | 2021-03-01 | Anti-sirp-beta1 antibodies and methods of use thereof |
SG11202108734VA (en) | 2021-09-29 | Anti-trem2 antibodies and methods of use thereof |
SG11202104217QA (en) | 2021-05-28 | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
IL290741A (en) | 2022-04-01 | Anti-cd96 antibodies and methods of use thereof |
IL262747A (en) | 2018-12-31 | Anti-kv1.3 antibodies, and methods of production and use thereof |
SG11202108403UA (en) | 2021-08-30 | Anti-clec2d antibodies and methods of use thereof |
IL289952A (en) | 2022-03-01 | Anti-ms4a4a antibodies and methods of use thereof |
IL280338A (en) | 2021-03-01 | Anti-siglec-5 antibodies and methods of use thereof |
IL291461A (en) | 2022-05-01 | Anti-alpha-synuclein antibodies and methods of use thereof |
IL283884A (en) | 2021-07-29 | Anti-il-36 antibodies and methods of use thereof |
IL279227A (en) | 2021-01-31 | Anti-siglec-7 antibodies and methods of use thereof |